Статті в журналах з теми "Evernimicin"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-27 статей у журналах для дослідження на тему "Evernimicin".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
McNicholas, Paul M., David J. Najarian, Paul A. Mann, David Hesk, Roberta S. Hare, Karen J. Shaw, and Todd A. Black. "Evernimicin Binds Exclusively to the 50S Ribosomal Subunit and Inhibits Translation in Cell-Free Systems Derived from both Gram-Positive and Gram-Negative Bacteria." Antimicrobial Agents and Chemotherapy 44, no. 5 (May 1, 2000): 1121–26. http://dx.doi.org/10.1128/aac.44.5.1121-1126.2000.
Повний текст джерелаAdrian, Peter V., Wenjun Zhao, Todd A. Black, Karen J. Shaw, Roberta S. Hare, and Keith P. Klugman. "Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of Action." Antimicrobial Agents and Chemotherapy 44, no. 3 (March 1, 2000): 732–38. http://dx.doi.org/10.1128/aac.44.3.732-738.2000.
Повний текст джерелаMcNicholas, Paul M., Paul A. Mann, David J. Najarian, Lynn Miesel, Roberta S. Hare, and Todd A. Black. "Effects of Mutations in Ribosomal Protein L16 on Susceptibility and Accumulation of Evernimicin." Antimicrobial Agents and Chemotherapy 45, no. 1 (January 1, 2001): 79–83. http://dx.doi.org/10.1128/aac.45.1.79-83.2001.
Повний текст джерелаSouli, Maria, Claudie Thauvin-Eliopoulos, and George M. Eliopoulos. "In Vivo Activities of Evernimicin (SCH 27899) against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci in Experimental Endocarditis." Antimicrobial Agents and Chemotherapy 44, no. 10 (October 1, 2000): 2733–39. http://dx.doi.org/10.1128/aac.44.10.2733-2739.2000.
Повний текст джерелаBoucher, Helen W., Claudie Thauvin-Eliopoulos, David Loebenberg, and George M. Eliopoulos. "In Vivo Activity of Evernimicin (SCH 27899) against Methicillin-Resistant Staphylococcus aureus in Experimental Infective Endocarditis." Antimicrobial Agents and Chemotherapy 45, no. 1 (January 1, 2001): 208–11. http://dx.doi.org/10.1128/aac.45.1.208-211.2001.
Повний текст джерелаPavia, Charles S., Gary P. Wormser, John Nowakowski, and Anthony Cacciapuoti. "Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease." Antimicrobial Agents and Chemotherapy 45, no. 3 (March 1, 2001): 936–37. http://dx.doi.org/10.1128/aac.45.3.936-937.2001.
Повний текст джерелаAarestrup, Frank Møller, and Paul M. McNicholas. "Incidence of High-Level Evernimicin Resistance in Enterococcus faecium among Food Animals and Humans." Antimicrobial Agents and Chemotherapy 46, no. 9 (September 2002): 3088–90. http://dx.doi.org/10.1128/aac.46.9.3088-3090.2002.
Повний текст джерелаZbaida, Shmuel, Joan Brieland, Philip Krieter, David Loebenberg, Gopal Krishna, Debra Horne, Xiaowen Lu, et al. "In Vitro Uptake of SCH 27899 (Evernimicin) by Rat Alveolar Macrophages." Antimicrobial Agents and Chemotherapy 45, no. 3 (March 1, 2001): 959–61. http://dx.doi.org/10.1128/aac.45.3.959-961.2001.
Повний текст джерелаChampney, W. Scott, and Craig L. Tober. "Evernimicin (SCH27899) Inhibits both Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureusCells." Antimicrobial Agents and Chemotherapy 44, no. 6 (June 1, 2000): 1413–17. http://dx.doi.org/10.1128/aac.44.6.1413-1417.2000.
Повний текст джерелаAdrian, Peter V., Cara Mendrick, David Loebenberg, Paul McNicholas, Karen J. Shaw, Keith P. Klugman, Roberta S. Hare, and Todd A. Black. "Evernimicin (SCH27899) Inhibits a Novel Ribosome Target Site: Analysis of 23S Ribosomal DNA Mutants." Antimicrobial Agents and Chemotherapy 44, no. 11 (November 1, 2000): 3101–6. http://dx.doi.org/10.1128/aac.44.11.3101-3106.2000.
Повний текст джерелаKofoed, Christine B., and Birte Vester. "Interaction of Avilamycin with Ribosomes and Resistance Caused by Mutations in 23S rRNA." Antimicrobial Agents and Chemotherapy 46, no. 11 (November 2002): 3339–42. http://dx.doi.org/10.1128/aac.46.11.3339-3342.2002.
Повний текст джерелаKenny, George E., and Frank D. Cartwright. "Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones." Antimicrobial Agents and Chemotherapy 45, no. 9 (September 1, 2001): 2604–8. http://dx.doi.org/10.1128/aac.45.9.2604-2608.2001.
Повний текст джерелаMann, Paul A., Liqun Xiong, Alexander S. Mankin, Andrew S. Chau, Cara A. Mendrick, David J. Najarian, Christina A. Cramer, et al. "EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance." Molecular Microbiology 41, no. 6 (September 2001): 1349–56. http://dx.doi.org/10.1046/j.1365-2958.2001.02602.x.
Повний текст джерелаDrusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. "Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint." Antimicrobial Agents and Chemotherapy 45, no. 1 (January 1, 2001): 13–22. http://dx.doi.org/10.1128/aac.45.1.13-22.2001.
Повний текст джерелаZarazaga, Myriam, Carmen Tenorio, Rosa Del Campo, Fernanda Ruiz-Larrea, and Carmen Torres. "Mutations in Ribosomal Protein L16 and in 23S rRNA in Enterococcus Strains for Which Evernimicin MICs Differ." Antimicrobial Agents and Chemotherapy 46, no. 11 (November 2002): 3657–59. http://dx.doi.org/10.1128/aac.46.11.3657-3659.2002.
Повний текст джерелаHamilton-Miller, J. M. T., S. Shah, and D. Loebenberg. "Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies." Clinical Microbiology and Infection 7, no. 6 (June 2001): 339–40. http://dx.doi.org/10.1046/j.1198-743x.2001.00252.x.
Повний текст джерелаAarestrup, Frank Møller, and Lars Bogø Jensen. "Presence of Variations in Ribosomal Protein L16 Corresponding to Susceptibility of Enterococci to Oligosaccharides (Avilamycin and Evernimicin)." Antimicrobial Agents and Chemotherapy 44, no. 12 (December 1, 2000): 3425–27. http://dx.doi.org/10.1128/aac.44.12.3425-3427.2000.
Повний текст джерелаTanaka, K. "In vitro activity of an evernimicin derivative, SCH27899, against anaerobic bacteria and Propionibacterium acnes." Journal of Antimicrobial Chemotherapy 46, no. 3 (September 1, 2000): 465–69. http://dx.doi.org/10.1093/jac/46.3.465.
Повний текст джерелаZhong, Ruyun, Abraham Hernandez, Kevin B. Alton, Narendra S. Kishnani, and James E. Patrick. "High-performance liquid chromatographic method for the quantification of unbound evernimicin in human plasma ultrafiltrate." Journal of Chromatography B 772, no. 1 (May 2002): 191–95. http://dx.doi.org/10.1016/s1570-0232(02)00084-3.
Повний текст джерелаArenz, Stefan, Manuel F. Juette, Michael Graf, Fabian Nguyen, Paul Huter, Yury S. Polikanov, Scott C. Blanchard, and Daniel N. Wilson. "Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome." Proceedings of the National Academy of Sciences 113, no. 27 (June 21, 2016): 7527–32. http://dx.doi.org/10.1073/pnas.1604790113.
Повний текст джерелаGoering, R., C. E. Nord, R. Hare, and F. Sabatelli. "In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study." Clinical Microbiology and Infection 6, no. 10 (October 2000): 549–56. http://dx.doi.org/10.1046/j.1469-0691.2000.00167.x.
Повний текст джерелаBelanger, Aimee E., and Thomas R. Shryock. "Avilamycin did not play a role in the discontinuation of evernimicin as a clinical drug candidate." Journal of Mass Spectrometry 40, no. 8 (August 2005): 1109. http://dx.doi.org/10.1002/jms.889.
Повний текст джерелаBelova, L., T. Tenson, L. Xiong, P. M. McNicholas, and A. S. Mankin. "A novel site of antibiotic action in the ribosome: Interaction of evernimicin with the large ribosomal subunit." Proceedings of the National Academy of Sciences 98, no. 7 (March 20, 2001): 3726–31. http://dx.doi.org/10.1073/pnas.071527498.
Повний текст джерелаHosted, T. J., T. X. Wang, D. C. Alexander, and A. C. Horan. "Characterization of the biosynthetic gene cluster for the oligosaccharide antibiotic, Evernimicin, in Micromonospora carbonacea var. africana ATCC39149." Journal of Industrial Microbiology and Biotechnology 27, no. 6 (December 1, 2001): 386–92. http://dx.doi.org/10.1038/sj.jim.7000189.
Повний текст джерелаKrupkin, Miri, Itai Wekselman, Donna Matzov, Zohar Eyal, Yael Diskin Posner, Haim Rozenberg, Ella Zimmerman, Anat Bashan, and Ada Yonath. "Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding." Proceedings of the National Academy of Sciences 113, no. 44 (October 19, 2016): E6796—E6805. http://dx.doi.org/10.1073/pnas.1614297113.
Повний текст джерелаJones, R. N. "In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial." Journal of Antimicrobial Chemotherapy 47, no. 1 (January 1, 2001): 15–25. http://dx.doi.org/10.1093/jac/47.1.15.
Повний текст джерела"P:5/3 – Evernimicin." Clinical Microbiology and Infection 6 (May 2000): 83. http://dx.doi.org/10.1016/s1198-743x(15)30166-x.
Повний текст джерела